KPV
Immune ModulationImmune & InflammationimmuneAnti-Inflammatory TripeptideImmune & Anti-inflammatoryImmuneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Skin
Overview
KPV is a tripeptide (lysine-proline-valine) that forms the C-terminal end of alpha-MSH. It is studied as an anti-inflammatory agent, particularly for gut and skin inflammation. It enters cells via the PepT1 transporter and appears to interfere with NF-kB, reducing pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6. Its action is largely receptor-independent, not activating classic melanocortin receptors.
Primary Uses
Anti-inflammatory treatment
Inflammatory bowel disease (IBD)
Skin conditions (dermatitis, wound healing)
Reducing colonic inflammation
Preserving intestinal barrier integrity
Suppressing inflammatory gene transcription
Reducing TNF-alpha, IL-6, and IL-1beta production
Gastrointestinal inflammation (IBD, colitis)
Skin inflammation (dermatitis)
Immune modulation
Antimicrobial activity against Staphylococcus aureus and Candida albicans
Gut inflammation models
Dermatology/topical studies
Antimicrobial peptide research
IBD-related signaling
Systemic Inflammation
Autoimmune Modulation
Joint Inflammation
IBD Support
Intestinal Barrier Repair
Microbiome Balance
Psoriasis/Dermatitis
Skin Inflammation
Anti-inflammatory effects
Gut barrier protection
Oxidative stress reduction
Skin health
Gut inflammation
Skin conditions
Inflammatory bowel disease (preclinical)
Colitis (preclinical)
Colitis-associated cancer (preclinical)
Protocol Reference
Dose
250–500 mcg
Frequency
Once Daily (subq) Or Twice Daily (oral)
Half-life
Often cited around 1-2 hours; human PK data limited
Route
Oral · Subcutaneous
Evidence
Preclinical / Preclinical (animal studies); no large-scale human clinical trials completed / Emerging / B (disputed)
Research References· 6
Research Models
HumanIn vitroMousemurine
Also in Immune Modulation